This week's Pod dives into a new VEGF-R inhibitor, fruquintinib.  We also ask if FLAURA2, osimertinib + chemotherapy in combination, will become a new standard of care in EGFR-mutated metastatic NSCLC.

This week's Pod dives into a new VEGF-R inhibitor, fruquintinib. We also ask if FLAURA2, osimertinib + chemotherapy in combination, will become a new standard of care in EGFR-mutated metastatic NSCLC.

Fruquintinib And Osimertinib-Chemo in Combo?

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Science

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Share Fruquintinib And Osimertinib-Chemo in Combo?

Sign up to save your podcasts

Fruquintinib And Osimertinib-Chemo in Combo?

Fruquintinib And Osimertinib-Chemo in Combo?

More shows like OncoPharm

JAMA Editors' Summary

NEJM This Week

JAMA Clinical Reviews

The Curbsiders Internal Medicine Podcast

Up First from NPR

Core IM | Internal Medicine Podcast

The ONS Podcast

ASCO Guidelines

Real Life Pharmacology - Pharmacology Education for Health Care Professionals

OncLive® On Air

Harrison's PodClass: Internal Medicine Cases and Board Prep

The Curious Clinicians

WolverHeme Happy Hour

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions